id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0669-0009,FDA,FDA-2021-D-0669,S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals; Guidance for Industry,Other,Guidance,2022-11-02T04:00:00Z,2022,11,2022-11-02T04:00:00Z,,2024-11-12T23:47:13Z,,1,0,090000648547b844
FDA-2021-D-0669-0008,FDA,FDA-2021-D-0669,S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals; International Council for Harmonisation; Guidance for Industry; Availability,Notice,Notice of Availability,2022-11-02T04:00:00Z,2022,11,,,2022-11-02T12:34:04Z,2022-23787,0,0,090000648547b3db
FDA-2021-D-0669-0002,FDA,FDA-2021-D-0669,S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals,Other,Guidance,2021-10-05T04:00:00Z,2021,10,,,2022-11-02T12:40:47Z,,0,0,0900006484dba814
FDA-2021-D-0669-0001,FDA,FDA-2021-D-0669,"S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals; International Council for Harmonisation; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2021-10-05T04:00:00Z,2021,10,2021-10-05T04:00:00Z,2021-12-07T04:59:59Z,2021-12-07T02:00:53Z,2021-21692,0,0,0900006484dba4de